CareDx, Inc (CDNA) Income Statement
CDNA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCDNA revenue and net income
Where CDNA's revenue goes
2025Each bar shows an amount and its share of revenue. CDNA kept −5.6% of revenue as net income.
CDNA profit margins
CDNA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +13.8% | +5.7% | +14.6% | +29.7% |
| Gross profit | +14.5% | +7.0% | +14.7% | +30.5% |
| Operating income | −161.5% | — | — | — |
| Net income | −140.6% | — | — | — |
| EPS (diluted) | +11.1% | — | +49.6% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CDNA quarterly EPS vs estimates
CareDx beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 29, 2026 (estimate $0.07).
CDNA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M | $192.2M | $127.1M | $76.6M | $48.3M | $40.6M |
| Cost of revenue | $123.2M | $109.6M | $102.0M | $112.2M | $97.4M | $63.1M | $45.5M | $33.0M | $21.4M | $21.1M |
| Gross profit | $256.6M | $224.2M | $178.3M | $209.6M | $199.0M | $129.1M | $81.6M | $43.6M | $27.0M | $19.5M |
| Research & development | $71.4M | $72.4M | $81.9M | $90.4M | $76.5M | $48.9M | $30.7M | $14.5M | $12.4M | $12.4M |
| Sales, general & admin | $210.2M | $123.8M | $201.2M | $196.4M | $152.2M | $102.7M | $75.4M | $43.6M | $31.7M | $31.9M |
| Total operating expenses | $281.6M | $183.4M | $381.7M | $286.8M | $228.7M | $151.6M | $106.1M | $58.1M | $44.1M | $44.3M |
| Operating income | −$25.1M | $40.8M | −$203.4M | −$77.2M | −$29.7M | −$22.5M | −$24.5M | −$15.6M | −$20.3M | −$37.3M |
| Interest income | $9.2M | $11.8M | $11.9M | $3.8M | $160,000 | $271,000 | $1.3M | $26.7M | $35.5M | $2.1M |
| Interest expense | — | — | — | $3.8M | $9.6M | $271,000 | $3.7M | $3.7M | $5.9M | $1.9M |
| Income before taxes | −$21.1M | $52.9M | −$190.1M | −$76.2M | −$32.1M | −$19.8M | −$23.9M | −$48.2M | −$57.3M | −$41.4M |
| Income taxes | $271,000 | $310,000 | $141,000 | $379,000 | −$1.4M | −$1.0M | −$2.0M | −$1.4M | −$1.7M | −$1.6M |
| Net income | −$21.4M | $52.5M | −$190.3M | −$76.6M | −$30.7M | −$18.7M | −$22.0M | −$46.8M | −$55.5M | −$39.5M |
| EBITDA | −$4.7M | −$34.0M | −$84.9M | −$60.2M | −$20.2M | −$8.2M | −$17.4M | −$11.4M | −$14.6M | −$17.8M |
| EPS (diluted) | $0.60 | $0.54 | −$0.64 | −$0.39 | $0.29 | $0.08 | −$0.08 | −$0.18 | −$0.54 | −$1.54 |
| Gross margin | 67.6% | 67.2% | 63.6% | 65.1% | 67.1% | 67.2% | 64.2% | 56.9% | 55.8% | 48.0% |
| Operating margin | −6.6% | 12.2% | −72.5% | −24.0% | −10.0% | −11.7% | −19.3% | −20.3% | −42.0% | −91.9% |
| Net margin | −5.6% | 15.7% | −67.9% | −23.8% | −10.3% | −9.7% | −17.3% | −61.1% | −114.8% | −97.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $131.9M | $117.7M | $108.4M | $100.1M | $86.7M | $84.7M | $86.6M | $82.9M | $92.3M | $72.0M | $65.6M | $67.2M |
| Cost of revenue | $35.0M | $33.6M | $35.5M | $30.7M | $28.7M | $28.4M | $28.2M | $27.6M | $28.0M | $25.9M | $25.6M | $24.5M |
| Gross profit | $97.0M | $84.1M | $72.9M | $69.4M | $58.0M | $56.3M | $58.4M | $55.3M | $64.3M | $46.1M | $40.0M | $42.7M |
| Research & development | $22.4M | $21.4M | $19.3M | $16.8M | $16.8M | $18.5M | $16.5M | $17.5M | $19.7M | $18.7M | $18.3M | $19.0M |
| Sales, general & admin | $74.3M | $60.9M | $59.6M | $52.9M | $52.0M | $45.8M | $40.7M | $48.3M | $51.9M | $46.7M | $46.5M | $52.4M |
| Total operating expenses | $96.7M | $82.3M | $78.9M | $69.6M | $68.8M | $64.3M | $70.3M | $65.8M | $71.6M | $65.5M | $66.3M | $71.4M |
| Operating income | $257,000 | $1.8M | −$6.0M | −$246,000 | −$10.8M | −$8.0M | −$11.9M | −$10.5M | −$7.3M | −$19.3M | −$40.7M | −$28.8M |
| Interest income | $1.7M | $1.9M | $2.0M | $2.0M | $2.4M | $2.8M | $3.1M | $3.0M | $2.8M | $2.9M | $3.2M | $3.2M |
| Income before taxes | $114.5M | $2.8M | −$3.8M | $1.7M | −$8.7M | −$10.3M | $87.9M | −$7.2M | −$4.6M | −$16.7M | −$117.9M | −$23.6M |
| Income taxes | $3.9M | −$32,000 | $345,000 | −$15,000 | −$117,000 | $58,000 | −$171,000 | $200,000 | $22,000 | −$83,000 | $165,000 | −$80,000 |
| Net income | $110.6M | $2.8M | −$4.1M | $1.7M | −$8.6M | −$10.4M | $78.0M | −$7.4M | −$4.6M | −$16.7M | −$118.1M | −$23.5M |
| EBITDA | $4.3M | $7.1M | −$780,000 | $4.9M | −$5.7M | −$3.1M | −$7.2M | −$2.3M | $356,000 | −$11.5M | −$35.6M | −$18.5M |
| EPS (diluted) | $0.17 | $0.34 | $0.12 | $0.28 | $0.10 | $0.10 | $0.18 | $0.14 | $0.25 | −$0.03 | −$0.17 | −$0.18 |
| Gross margin | 73.5% | 71.4% | 67.2% | 69.4% | 66.9% | 66.4% | 67.5% | 66.7% | 69.7% | 64.0% | 60.9% | 63.5% |
| Operating margin | 0.2% | 1.5% | −5.6% | −0.2% | −12.4% | −9.5% | −13.8% | −12.7% | −7.9% | −26.8% | −62.0% | −42.8% |
| Net margin | 83.8% | 2.4% | −3.8% | 1.7% | −9.9% | −12.2% | 90.1% | −8.9% | −5.0% | −23.1% | −180.1% | −35.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CDNA's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CDNA financial results
In fiscal year 2025 (ended December 31, 2025), CareDx reported revenue of $379.8 million, up 13.8% from the year before. It had a net loss of $21.4 million, a net profit margin of −5.6%. Diluted earnings per share came to $0.60. Over five years revenue grew at an average rate of 14.6% a year.
See the CDNA stock overview for the latest quote and news, or the CDNA chart for price history and technical indicators.
CDNA income statement FAQ
What is CareDx's annual revenue?
CareDx reported total revenue of $379.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 13.8% from $333.8 million the previous year.
Is CareDx profitable?
No. CareDx reported a net loss of $21.4 million in fiscal 2025, a net profit margin of −5.6%; its operating margin was −6.6%.
What is CareDx's gross margin?
CareDx's gross margin was 67.6% in fiscal 2025: for every $100 of revenue, CareDx kept $68 after the direct cost of its products and services.
How much does CareDx spend on research and development?
CareDx spent $71.4 million on research and development in fiscal 2025, 18.8% of revenue.
How fast is CareDx growing?
Revenue grew 14.6% a year on average over the last five fiscal years, from $192.2 million to $379.8 million.
What are CareDx's earnings per share?
CareDx earned $0.60 per diluted share in fiscal 2025, compared with $0.54 a year earlier.
When will CareDx report its next earnings?
CareDx is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes.
When does CareDx's fiscal year end?
CareDx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.